ArticleBlood cancer discovery2026
Multiplexed Imaging Reveals Immune-Metabolic Niches in Multiple Myeloma Linked to Progression and Bone Disease.
Article in Blood cancer discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Targeting the immunological synapse in multiple myeloma.Discover oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Multiple myeloma is a plasma cell (PC) cancer that depends on the bone marrow (BM) microenvironment for disease establishment and progression. In this study, we spatially mapped BM biopsies from patients with multiple myeloma, smoldering multiple myeloma, and monoclonal gammopathy of undetermined significance by imaging mass cytometry. We found that PCs near bone surfaces displayed markers of quiescence and demonstrated a distance-to-bone-dependent expression of IL32 in patients with bone disease, consistent with their role in promoting bone loss in multiple myeloma. We identified two distinct PC neighborhoods termed PC OXPHOS, characterized by focal PC growth, enrichment of endothelial cells, and oxidative phosphorylation, and PC MYELOID, characterized by PCs interspersed with immune cells, featuring a glycolytic phenotype. Notably, imaging-inferred interactions between PCs and CD4+ T cells were an independent negative predictor for progression-free survival (PFS). Our work underscores spatial context as a key factor in understanding multiple myeloma pathogenesis and the potential for spatial analyses to improve multiple myeloma risk stratification. SIGNIFICANCE: This study demonstrates that multiple myeloma cells in different neighborhoods experience unique metabolic conditions and immune environments, and that neighbor preference of CD4+ T cells and PCs is associated with poorer PFS. These data highlight the value of spatially resolved analyses in uncovering potential pathophysiologic mechanisms of multiple myeloma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.